Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Nasopharyngeal Carcinoma 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Sarcoma 2Respiratory Tract Diseases 2Lung Diseases 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Solid Tumor 2Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Recurrence 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non Squamous Non Small Cell Lung Cancer 1Neoplasms by Site 1Neoplasm Metastasis 1Lymphoma, Extranodal NK-T-Cell 1Hodgkin Disease 1

Interventions

pembrolizumab 98Gemcitabine 70Paclitaxel 59Docetaxel 52Carboplatin 49Cisplatin 40Nivolumab 39Capecitabine 35Pemetrexed 33Fluorouracil 32Bevacizumab 32Cetuximab 31130-nm albumin-bound paclitaxel 28Trastuzumab 26Irinotecan 24Albumin-Bound Paclitaxel 24Fulvestrant 22Leucovorin 20Oxaliplatin 18Panitumumab 17abemaciclib 16Ipilimumab 16Cyclophosphamide 15cemiplimab 14atezolizumab 14Letrozole 14palbociclib 12Lapatinib 12Drug Therapy 12Doxorubicin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Metastasis × camrelizumab × Clear all
NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
543 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡